Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer.

Prostate cancer (PC) patients die from progression to androgen independence (AI) and chemoresistance (CR). Protein kinase Cmu (PKCmu) a novel member of the PKC family of signal transduction proteins is downregulated in AI PC. Studying PKCmu interactors in the yeast two-hybrid system identified metallothionein 2A (MT 2A) as an interactor of PKCmu kinase domain (KD) in PC, which was quantified by beta-gal assay, confirmed in PC cells by immunoprecipitation, and PKCmu-MT 2A co-localization in vivo by immunofluorescence studies. PKCmu domain interaction studies revealed that MT 2A interacted strongly with KD, relatively weakly with C1, and failed to interact with C2, PH or kinase mutant domains. Peptide library and in silico analysis strongly suggest that MT 2A is a novel substrate of PKCmu and our data indicate that the PKCmu-MT 2A interaction depends on PKCmu kinase activity. Because metallothioneins are associated with cell proliferation and CR, the PKCmu-MT 2A interaction may contribute to CR and/or AI in PC.

[1]  A. Toker.  Signaling through protein kinase C. , 1998, Frontiers in bioscience : a journal and virtual library.

[2]  C. Tohyama,et al.  Testosterone-dependent induction of metallothionein in genital organs of male rats. , 1996, The Biochemical journal.

[3]  T. Iglesias,et al.  The Pleckstrin Homology Domain of Protein Kinase D Interacts Preferentially with the η Isoform of Protein Kinase C* , 1999, The Journal of Biological Chemistry.

[4]  N. Blom,et al.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. , 1999, Journal of molecular biology.

[5]  E. Rozengurt,et al.  Protein Kinase C Phosphorylates Protein Kinase D Activation Loop Ser744 and Ser748 and Releases Autoinhibition by the Pleckstrin Homology Domain* , 2003, The Journal of Biological Chemistry.

[6]  Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. , 1997, Clinical and investigative medicine. Medecine clinique et experimentale.

[7]  T. Soderling,et al.  A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1 , 1996, Molecular and cellular biology.

[8]  M Vasák,et al.  Metallothioneins: new functional and structural insights. , 2000, Current opinion in chemical biology.

[9]  L. Jin,et al.  Immunohistochemical localization of metallothionein in human prostate cancer. , 1996, The Journal of urology.

[10]  P. Storz,et al.  Bruton's tyrosine kinase (Btk) associates with protein kinase C μ , 1999 .

[11]  P. Vihko,et al.  The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. , 1998, Biochemical and biophysical research communications.

[12]  S. Ho,et al.  Ribozyme‐mediated downregulation of human metallothionein IIa induces apoptosis in human prostate and ovarian cancer cell lines , 2002, Molecular carcinogenesis.

[13]  J. Prestle,et al.  PKCu is a novel, atypical member of the protein kinase C family. , 1994, The Journal of biological chemistry.

[14]  Zhou Songyang,et al.  Determination of the Specific Substrate Sequence Motifs of Protein Kinase C Isozymes* , 1997, The Journal of Biological Chemistry.

[15]  P. Storz,et al.  Protein Kinase C μ Is Regulated by the Multifunctional Chaperon Protein p32* , 2000, The Journal of Biological Chemistry.

[16]  P. Coyle,et al.  Metallothionein: the multipurpose protein , 2002, Cellular and Molecular Life Sciences CMLS.

[17]  K. Pienta,et al.  The Current State of Hormonal Therapy for Prostate Cancer , 2002, CA: a cancer journal for clinicians.

[18]  M. Webber,et al.  Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. , 1988, Cancer research.

[19]  A. Abdel‐Mageed,et al.  Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. , 1998, Cancer research.

[20]  P. Rao,et al.  Protein kinase C μ is down-regulated in androgen-independent prostate cancer , 2003 .

[21]  W. Fair,et al.  Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[22]  J. Prestle,et al.  Protein kinase C mu is located at the Golgi compartment , 1996, The Journal of cell biology.

[23]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.

[24]  R. Palmiter.  The elusive function of metallothioneins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[26]  P. Storz,et al.  Protein Kinase C μ Is Negatively Regulated by 14-3-3 Signal Transduction Proteins* , 1999, The Journal of Biological Chemistry.